The dynamics of quantitative SARS-CoV-2 antispike IgG response to BNT162b2 vaccination

Article Virology

Clinical validation of an immunochromatographic SARS-Cov-2 IgM/IgG antibody assay with Japanese cohort

Shun Kaneko et al.

Summary: This study evaluated the clinical performance of the colloidal gold immunochromatography assay for SARS-CoV-2 IgM/IgG antibodies in COVID-19 patients, showing a high sensitivity and specificity for the diagnosis of the disease.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021

Kamal Abu Jabal et al.

Summary: An analysis of 514 Israeli healthcare workers showed that the BNT162b2 mRNA COVID-19 vaccine had similar immunogenicity by ethnicity and sex, but decreased with age. Individuals with prior COVID-19 infection had significantly higher antibody titres compared to those who were naive, regardless of pre-vaccination IgG levels.

EUROSURVEILLANCE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Sharon Amit et al.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

The dawn of mRNA vaccines: The COVID-19 case

Rein Verbeke et al.

Summary: In less than a year since the COVID-19 pandemic outbreak, mRNA vaccines have made significant progress, with two receiving emergency use authorization and one moving to phase 3 clinical testing. These mRNA vaccines represent a new class of vaccine products, encoding the SARS-CoV-2 Spike glycoprotein to deliver mRNA to cells. The review provides a detailed overview of the composition, clinical performance, and design considerations of the most advanced mRNA vaccines, highlighting new insights and areas for future research and optimization.

JOURNAL OF CONTROLLED RELEASE (2021)

添加到收藏夹

Article Medicine, General & Internal